Oncological Outcomes in Patients with Delayed Cytoreductive Surgery During COVID Times-Reference-Cited by-同舟云学术

Oncological Outcomes in Patients with Delayed Cytoreductive Surgery During COVID Times

Published:2024-09-03 Issue: Volume: Page:
ISSN:0975-7651
Container-title:Indian Journal of Surgical Oncology
language:en
Short-container-title:Indian J Surg Oncol

Author:

Barmon Debabrata,Kaur Eshwarya Jessy^ORCID,Baruah Upasana,Begum Dimpy,Roy Partha Sarthi,Khanikar Duncan,Bhattacharyya Mouchumee,Ahmed Shiraj,Kumar Mahendra,Patra Sharda,Sharma Ratnadeep

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13193-024-02083-w.pdf

Reference14 articles.

1. Angeles MA, Cabarrou B, Gil-Moreno A, Pérez-Benavente A, Spagnolo E, Rychlik A et al 2021 Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer. J Gynecol Oncol 32(6). https://doi.org/10.3802/jgo.2021.32.e78

2. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I et al (2019) ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672–705

3. Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C et al (2020) Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. Int Multicenter Study Gynecol Oncol 159(2):434–441

4. Yao SE, Tripcony L, Sanday K, Robertson J, Perrin L, Chetty N et al (2020) Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Gynecol Cancer 30(12):1935–1942

5. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S et al (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer Oxf Engl 1990 62:132–7